In:
Clinical and Developmental Immunology, Wiley, Vol. 2012 ( 2012), p. 1-6
Abstract:
Objectives . The aim of this study was to evaluate clinical and US-PD parameters in PsA during adalimumab treatment. Methods . A retrospective study has been conducted in forty patients affected by moderate-to-severe peripheral PsA. Clinical, laboratory, and US-PD evaluations were performed at baseline, after 4, 12, and 24 weeks of treatment. They included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), visual analogue scale (VAS), Health Assessment Questionnaire (HAQ) modified for Spondyloarthritis, Psoriasis Area Severity Index (PASI) score, the 28-joint Disease Activity Score (DAS 28), and US-PD assessment. US-PD findings were scored according to a semiquantitative scale (ranging 0–3) for synovial proliferation (SP), joint effusion (SE), bone erosions (BE), and PD. Results . Data obtained for clinical, laboratory findings and US-PD evaluation showed statistical significant improvement in all the measures performed except for BE. A significant parallel decrease in SE, SP, and PD values were demonstrated. Conclusion . This study demonstrated that US-PD is a valid technique in monitoring the response to adalimumab in moderate-to-severe PsA.
Type of Medium:
Online Resource
ISSN:
1740-2522
,
1740-2530
Language:
English
Publisher:
Wiley
Publication Date:
2012
detail.hit.zdb_id:
2119272-8
detail.hit.zdb_id:
2119646-1
Permalink